PT2524700E - Vacina de glicoproteína mucinosa (muc-1) - Google Patents

Vacina de glicoproteína mucinosa (muc-1) Download PDF

Info

Publication number
PT2524700E
PT2524700E PT111962288T PT11196228T PT2524700E PT 2524700 E PT2524700 E PT 2524700E PT 111962288 T PT111962288 T PT 111962288T PT 11196228 T PT11196228 T PT 11196228T PT 2524700 E PT2524700 E PT 2524700E
Authority
PT
Portugal
Prior art keywords
muc
vaccine
treatment
prostate cancer
mucinous glycoprotein
Prior art date
Application number
PT111962288T
Other languages
English (en)
Inventor
Michael Longenecker
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Publication of PT2524700E publication Critical patent/PT2524700E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT111962288T 2004-04-01 2005-04-01 Vacina de glicoproteína mucinosa (muc-1) PT2524700E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55813904P 2004-04-01 2004-04-01
US57680404P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
PT2524700E true PT2524700E (pt) 2016-02-29

Family

ID=35428714

Family Applications (2)

Application Number Title Priority Date Filing Date
PT57696098T PT1737485E (pt) 2004-04-01 2005-04-01 Vacina da glicoproteína mucina (muc-1)
PT111962288T PT2524700E (pt) 2004-04-01 2005-04-01 Vacina de glicoproteína mucinosa (muc-1)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT57696098T PT1737485E (pt) 2004-04-01 2005-04-01 Vacina da glicoproteína mucina (muc-1)

Country Status (16)

Country Link
US (2) US9173929B2 (pt)
EP (2) EP2524700B1 (pt)
JP (3) JP5590768B2 (pt)
CN (2) CN103933556A (pt)
AR (1) AR051350A1 (pt)
AU (1) AU2005244675B2 (pt)
BR (1) BRPI0509552A (pt)
CA (1) CA2562990A1 (pt)
DK (2) DK2524700T3 (pt)
ES (2) ES2560808T3 (pt)
HK (1) HK1109574A1 (pt)
HU (1) HUE027378T2 (pt)
PL (2) PL2524700T3 (pt)
PT (2) PT1737485E (pt)
TW (2) TW201204410A (pt)
WO (1) WO2005112546A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377275B1 (en) 2001-03-27 2006-10-25 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
CA2482477A1 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PL1896051T3 (pl) * 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
AU2012268892B2 (en) * 2005-06-28 2016-05-26 Oncothyreon Inc. Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
EA020604B1 (ru) * 2008-12-17 2014-12-30 Онкотиреон, Инк. Композиция, содержащая липосомы малого размера, и способ ее получения
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
WO2011133429A1 (en) 2010-04-19 2011-10-27 Ezose Sciences, Inc Cancer-related glycopeptide epitopes, antibodies and methods of use
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
PT3427748T (pt) 2011-06-24 2022-05-03 Nono Inc Terapia de combinação para isquemia
DE102011085695A1 (de) * 2011-11-03 2013-05-08 Jörg Pohl Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CA2912269A1 (en) 2013-05-14 2014-11-20 Merck Patent Gmbh Method of treating lung cancer by vaccination with muc-1 lipopeptide
KR20160043103A (ko) * 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110393797A (zh) * 2019-05-27 2019-11-01 南开大学 基于糖脂佐剂的糖肽疫苗的制备方法与应用
WO2022125956A1 (en) * 2020-12-11 2022-06-16 Trustees Of Boston University Immunomodulatory lipopolysaccharide compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
DE3683688D1 (de) 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
ES2085920T3 (es) 1989-06-23 1996-06-16 Liposome Co Inc Liposomas dirigidos y metodos de acoplamiento liposoma-proteina.
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2001510440A (ja) * 1996-03-20 2001-07-31 スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ ムチン接合体ペプチドワクチン
ATE273320T1 (de) 1996-04-11 2004-08-15 Univ British Columbia Fusogene liposomen
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
AU727863B2 (en) 1997-05-08 2001-01-04 Oncothyreon Inc. Method for generating activated T-cells and antigen-pulsed antigen-presenting cells
JPH11139961A (ja) 1997-11-06 1999-05-25 Taisho Pharmaceut Co Ltd リポソームの製造方法
JP2002509102A (ja) 1998-01-16 2002-03-26 バイオミラ・ユーエスエイ・インコーポレイテッド リポマトリックス製剤
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US6104536A (en) 1998-09-18 2000-08-15 3M Innovative Properties Company High efficiency polarization converter including input and output lenslet arrays
JP2002529240A (ja) 1998-11-13 2002-09-10 オプタイム セラピュウティクス， インコーポレイテッド リポソーム生成のための方法および装置
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
DE60018761T2 (de) 1999-08-18 2006-02-02 Altarex Medical Corp., Edmonton Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
PT1210430E (pt) 1999-09-08 2006-12-29 Imp Cancer Res Tech Péptidos derivados de muc-1
JP2003514824A (ja) 1999-11-15 2003-04-22 ビオミラ，インコーポレーテッド 合成脂質−ａ類似体およびその使用
CA2404327A1 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
AU1999802A (en) * 2000-12-01 2002-06-11 Lawrence Boni Preparation of large liposomes by infusion into peg
EP1377275B1 (en) 2001-03-27 2006-10-25 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
EP2263465A1 (en) * 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalent conjugate vaccine for cancer
JP3760467B2 (ja) 2002-04-09 2006-03-29 ソニー株式会社 コンテンツ再生装置および方法、記録媒体、並びにプログラム
CA2482477A1 (en) 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2004071638A2 (en) 2003-02-11 2004-08-26 Regents Of The University Of California, The Microfluidic devices and method for controlled viscous shearing and formation of amphiphilic vesicles
US9198645B2 (en) 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PL1896051T3 (pl) 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
JP5126874B2 (ja) 2007-05-21 2013-01-23 国立大学法人神戸大学 リポソーム製剤の製造方法
EA020604B1 (ru) 2008-12-17 2014-12-30 Онкотиреон, Инк. Композиция, содержащая липосомы малого размера, и способ ее получения

Also Published As

Publication number Publication date
JP5590768B2 (ja) 2014-09-17
DK1737485T3 (da) 2014-08-04
EP1737485B1 (en) 2014-05-07
EP2524700B1 (en) 2015-10-28
BRPI0509552A (pt) 2007-09-18
JP5868125B2 (ja) 2016-02-24
AR051350A1 (es) 2007-01-10
JP2014177479A (ja) 2014-09-25
EP1737485A4 (en) 2008-09-03
US20080131495A1 (en) 2008-06-05
US9173929B2 (en) 2015-11-03
HUE027378T2 (en) 2016-10-28
PL1737485T3 (pl) 2014-10-31
CA2562990A1 (en) 2005-12-01
PT1737485E (pt) 2014-08-22
JP2007530663A (ja) 2007-11-01
DK2524700T3 (en) 2016-02-01
PL2524700T3 (pl) 2016-04-29
CN1997388B (zh) 2014-03-26
EP2524700A1 (en) 2012-11-21
TW200538147A (en) 2005-12-01
ES2560808T3 (es) 2016-02-22
WO2005112546A2 (en) 2005-12-01
TWI395591B (zh) 2013-05-11
US20160082093A1 (en) 2016-03-24
TW201204410A (en) 2012-02-01
WO2005112546A3 (en) 2006-05-04
AU2005244675A1 (en) 2005-12-01
CN103933556A (zh) 2014-07-23
CN1997388A (zh) 2007-07-11
EP1737485A2 (en) 2007-01-03
JP2012092105A (ja) 2012-05-17
HK1109574A1 (en) 2008-06-13
ES2478006T3 (es) 2014-07-18
AU2005244675B2 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
PL2524700T3 (pl) Szczepionka z glikoproteiną mucynową (muc-1) do leczenia raka gruczołu krokowego
HUS1900030I1 (hu) Androgén receptor modulátorok a prosztatarák és androgén receptorral összefüggõ betegségek kezelésére
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
HK1219417A1 (zh) 用種粘蛋白狀糖蛋白 疫苗治療患者的方法
EP1599196A4 (en) ANTICANCER THERAPY
EP1613308A4 (en) CANCER TREATMENT METHODS
IL210400A0 (en) Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
EP1830847A4 (en) CANCER TREATMENT
EP1782827A4 (en) PEPTIDE VACCINE FOR THE TREATMENT OF CANCER
GB0428187D0 (en) Cancer treatment
GB0404675D0 (en) Cancer treatment
GB0410379D0 (en) Treatment of cancer
PL1618130T3 (pl) Szczepionka terapeutyczna przeciw nowotworom
EP1646282A4 (en) ANTICANCER GENETIC VACCINES
GB0423273D0 (en) Treatment of cancer
GB0414885D0 (en) Cancer therapy
GB0324482D0 (en) Methods for the treatment of cancer
GB0420845D0 (en) Treatment of cancer
GB0422225D0 (en) Treatment of cancer
IL180460A0 (en) Treatment of cancer
GB0421734D0 (en) Treatment of cancer
TWI340648B (en) Dna cancer vaccines